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Abstract:  The enormous variety of polysaccharides that can be extracted from marine 
plants and animal organisms or produced by marine bacteria means that the field of marine 
polysaccharides is constantly evolving. Recent advances in biological techniques allow 
high  levels  of  polysaccharides  of  interest  to  be  produced  in vitro.  Biotechnology  is  a 
powerful tool to obtain polysaccharides from a variety of micro-organisms, by controlling 
the growth conditions in a bioreactor while tailoring the production of biologically active 
compounds. Following an overview of the current knowledge on marine polysaccharides, 
with special attention to potential pharmaceutical applications and to more recent progress 
on the discovering of new polysaccharides with biological appealing characteristics, this 
review will focus on possible strategies for chemical or physical modification aimed to tailor 
the final properties of interest. 
Keywords: chitosan; alginate; agar; carrageenans; exopolysaccharides; chemical modification; 
drug delivery; gene delivery 
 
1. Introduction 
By  the  early  1950s,  an  impetus  to  learn  more  about  marine  organisms  arose.  The  earliest 
biologically active substance of marine origin was a toxin named holothurin, which was extracted by 
Nigrelli from a marine organism, the Actinopyga agassizi 1. Holothurin showed some antitumor 
activities  in  mice.  Since  then,  the  search  for  drugs  and  natural  products  of  interest  from  marine 
organisms has continued.  
The field of natural polysaccharides of marine origin is already large and expanding. Seaweeds are 
the most abundant source of polysaccharides, as alginates, agar and agarose as well as carrageenans. 
Table 1 gives an idea of the significant market of these polymers. Even cellulose and amylose have 
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been extracted from the macroalga ULVA, which is present along the coasts of Mediterranean Sea and 
in many lagoons including that of Venice 2. Chitin and chitosan are derived from the exoskeleton of 
marine crustaceans.  
Table 1. Polymers from macro-algae: 2003 market data [3].  
Product 
Production 
(t y
−1) 
Algae Harvested 
(t y
−1) 
Comments 
Carrageenan  33,000  168,400  Mainly Eucheuma and Kappaphycus 
Alginate  30,000  126,500  Laminaria, Macrocystis, Lessonia, Ascophyllum and others 
Agar  7,630  55,650  Mainly Gelidium and Gracilaria 
Recently,  microalgae  have  become  particularly  interesting  because  of  the  possibility  to  easily 
control the growth conditions in a bioreactor together with the demonstrated biochemical diversity of 
these organisms. Greater screening and selection efforts for biologically active compounds, including 
polysaccharides, have been developed 4. Examples of microalgae with commercial value are the 
unicellular red algae Porphyridium cruemtum and P. aerugineum, because of the large quantities of 
extracellular polysaccharides they produce 5. Lewis 6 screened a number of Chlamidomonas spp. 
for extracellular polysaccharide production. The most useful of these is C. mexicana, which yields up 
to 25% of its total organic production as polysaccharides. Moore and Tischer 7 have also reported 
high extracellular production levels for a number of green and blue-green algae. A number of patents 
have  been  issued  concerning  the  production  methods  and  applications  for  the  Porphyridium 
polysaccharide  8.  The  Porphyridium  polysaccharide  could  also  replace  existing  polysaccharide 
polymers such as carrageenan in biomedical applications. 
Interest is particularly growing towards extreme marine environments. It is obvious that the various 
extreme marine habitats (deep-sea hydrothermal vents, cold seeps, coastal hot springs, polar regions, 
hypersaline ponds, etc.) should represent a huge source of unknown and uncultivated bacteria. Many 
microbial exopolysaccharides (EPSs) produced by such extreme bacteria have unique properties; the 
bacteria must adopt special metabolic pathways to survive in extreme conditions, and so have better 
capacity to produce special bioactive compounds, including EPSs, than any other microorganisms. 
Moreover,  many  thermophylic  and  hyperthermophylic  bacteria  can  produce  EPS  under 
laboratory conditions. 
The present review focuses on progress in discovering and producing new marine polysaccharides 
of interest in pharmaceuticals. The more innovative and appealing fields of application and strategies 
for their modification are reported. Finally, an updating of recent literature on the more common 
marine polysaccharides is reported. 
2. Production, Applications and Modification Strategies of Marine Polysaccharides 
2.1. Biotechnology of Marine Extremophylic Bacteria 
The current opinion of most of the scientific community throughout the world is that knowledge of 
biochemical processes that adapted in extreme marine environments is the basis for discoveries in 
biotechnology. The fields of biotechnology that could benefit from miming the extremophiles are very 
broad and cover the search for new bioactive compounds for industrial, agricultural, environmental, Mar. Drugs 2010, 8 
 
 
2437 
pharmaceutical and medical uses. However, this potential remains to a large extent unexplored and, in 
respect of the drugs available on the market, only 30% have been developed from natural products and 
so far less than 10% have been isolated from marine organisms.  
Also, if difficulties in culturing marine organisms in the laboratory hold still true today 9,10, the 
process  of  industrialization  of  the  microbial  products  is  under  recent  exploitation.  Marine 
microorganisms are now considered as efficient producers of biologically active and/or chemically 
novel compounds, and no “supply issue” will appear since scaled-up productions can normally be 
achieved through bioreactors of any capacity that can be designed nowadays 11,12. Investigations in 
shake flasks are conducted with the prospect of large-scale processing in reactors.  
Different bioprocess engineering approaches are used for the production of polysaccharides from 
microorganisms. The major modes of operation in laboratory bioreactors and pilot implants are batch, 
fed-batch and continuous. Batch growth refers to culturing in a vessel with an initial charge of medium 
that is not altered by further nutrient addition or removal. This form of cultivation is simple and widely 
used  both  in  the  laboratory  and  industrially.  Growth,  product  formation  and  substrate  utilization 
terminate after a certain time interval. Submerged processes, where the organism is grown in a liquid 
medium, immobilized systems, in which the producing microorganism is restricted in a fixed space, 
and solid-state processes cultivations, in which the bioprocess is operated at low moisture levels or 
water activities, are widely employed in batch mode. In a continuous process, fresh nutrient medium is 
continually  added  to  a  well-stirred  culture  and  products  and  cells  are  simultaneously  withdrawn. 
Growth  and  product  formation  can  be  maintained  for  prolonged  periods,  and  the  system  usually 
reaches  a  steady  state  after  a  certain  period  of  time.  Continuous  processes  have  been  used  with 
suspended cells as well as with immobilized cells. In fed-batch culture, nutrients are continuously or 
semi-continuously  fed,  while  effluent  is  removed  discontinuously.  This  type  of  operation  is 
intermediate between batch and continuous processes, increasing the duration of batch cultivation and 
the overall reactor productivity. The fed-batch process is also applied in several bioprocesses.  
2.2. Hydrogels and Superporous Hydrogels  
Hydrogels based on cross-linked polysaccharides are used in key applications, such as drug delivery 
systems and tissue engineering. Polysaccharides may also form superabsorbent/superporous hydrogels. 
Superabsorbent hydrogels are hydrogels having a swelling ratio of a few hundred, and superporous 
hydrogels  are  furthermore  characterized  by  interconnected  pores  with  diameters  on  the  micron  to 
millimeter scale. Due to the presence of such big and interconnected pores, superporous hydrogels 
absorb a considerable amount of water in a very short period of time. These novel products may find 
applications in the development of drug and protein delivery systems, fast-dissolving tablets, occlusion 
devices for aneurysm treatment, scaffolding, cell culture, tissue engineering, hygiene products and 
many others 13. 
Sodium  alginate,  chitosan,  agar  and  carragenaan,  in  combination  with  polyacrylics  such  as 
poly(acrylic acid) and/or poly(acrylamide), form interpenetrating networks that give rise to superabsorbent 
and superporous hydrogels of enhanced elasticity 14–16. Hybrid hydrogels are multi-functional, as 
their properties depend on cross-linking density and medium pH, and their potential for controlled 
release  is  under  investigation  17.  Alternatively,  polysaccharides  have  been  cross-linked  by 
diacrylates also leading to superabsorbent and/or superporous full-polysaccharide hydrogels 18. Mar. Drugs 2010, 8 
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2.3. Bioadhesivs and Mucoadhesives from Marine Sources 
Natural  bioadhesives  are  polymeric  materials  that  may  consist  of  a  variety  of  substances,  but 
proteins and polysaccharides feature prominently. Many actives can be released via bioadhesives, as 
steroids, anti-inflammatory agents, pH sensitive peptides and small proteins such as insulin, and local 
treatments to alleviate pain in the buccal cavity. Requirements for a successful bioadhesive device for 
topical administration of active agents for prolonged periods of time are:  
-  maintain intimate contact with the site of application for 1 to 24 hours;  
-  be sufficiently adhesive and cohesive;  
-  guarantee controlled delivery of the active ingredients in wet and moist environments;  
-  be non-toxic, non irritating; 
-  be easily removable.  
Mucosal  membranes  are  lined  by  epithelial  or  endothelial  cells  having  “tight  junctions” 
(physiologically connect the enterocytes apically). Membranes are located in or on the skin, ear, eye, 
nose, gastrointestinal tract. Mucosa have limited permeability to therapeutic agents, especially if the 
molecular weight is higher than 500 Daltons, thus including most peptides and proteins.  
The tenacity with which marine algae cling to ships’ hulls and underwater constructions suggests a 
remarkable water-resistant adhesive capability. Responsible for fouling growths that reduce efficiency 
and  cause  costly  damage,  they  are  highly  resistant  to  mechanical  removal  and  all  but  the  most 
environmentally  unacceptable  chemical  preventive  agents.  The  responsible  bioadhesives  have 
extraordinarily  high  cohesive  strength  and  binding  strength  to  the  solid  surfaces,  enabling  the 
organisms to remain attached under tensional conditions that are, as a matter of fact, comparable to 
those found in a surgical environment. These qualities have indicated that this is a promising avenue of 
research in the hunt for more effective tissue adhesives for medical use, for example, surgery closures 
and bone glue, to replace painful traditional wound closure methods in the first case, and the use of 
metallic screws in the last one. Various algal bioadhesives have been isolated and characterized to find 
a safe and efficient candidate to be tested for use on human tissues. They are essentially based on 
gluing proteins; new formulations comprising polyphenolic proteins from mussels and marine origin 
polysaccharides are promising, especially as adhesive in ophthalmic therapies. 
A bioadhesive system based exclusively on polysaccharides and potentially useful for bone glue has 
been recently proposed by Hoffmann et al. 19. The authors developed a two-component system 
based on chitosan and oxidized dextran or starch. The bonding mechanism employs the reaction of 
aldehyde groups with amino groups in the presence of water, which covalently bind to each other in a 
Schiff’s  base  reaction.  Chitosan  was  chosen  as  amino  carrier,  and  was  previously  partially 
depolymerized with acid treatment to obtain a higher ratio between amino and aminoacetyl groups. 
Aldehyde  groups  on  starch  or  dextran  are  generated  by  oxidation  with  periodates.  In  addition,  
L-DOPA, an important element of mussel adhesives 20–22, was first conjugated to oxidized dextran 
or starch in analogy to the gluing mechanism of mussels and then oxidized to quinone. The quinone 
structure of L-DOPA, which is covalently bound to the aldehydes on dextran/starch, can also react with 
amino groups of chitosan by an imine formation or a Michael adduct formation. All of these reactions 
result  in  a  strong  adhesive  force  within  the  glue.  With  respect  to  fibrin  glue  and  cyanoacrylate 
adhesives, which are currently used in clinical practice, biomechanical studies revealed that the new Mar. Drugs 2010, 8 
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glue  is  superior  to  fibrin  glue,  but  has  less  adhesive  strength  than  cyanoacrylates.  Nonetheless, 
cyanoacrylates, besides having toxic side effects [23], are not resorbable and thus inhibit endogenous 
bone  repair.  In  conclusion,  because  both  components  are  natural,  biodegradable  polysaccharides, 
without any cytotoxic effects, this bioadhesive seems to be a good candidate for bone or soft tissue 
gluing applications in surgery. 
2.4. General Strategies of Modification of Marine Polysaccharides  
Natural polysaccharides can play a relevant role in biomedical and pharmaceutical applications, 
particularly in the field of drug delivery, for their intrinsic biocompatibility and potential low cost. 
Nevertheless, the properties of such materials sometimes do not fulfill the requirements for specific 
applications; hence, the development of strategies aiming to chemically and/or physically modify their 
structure and, consequently, their physical–chemical properties is gaining increasing interest 24,25.  
2.4.1. Blending 
The technique of blending is particularly attractive as it allows tailoring the properties of interest of 
the final material in a controlled manner while using polymers already known and widely accepted in 
the pharmaceutical field. Properties such as biodegradation rate, adhesion to biological substrates, drug 
solubility inside the polymer matrix, can be modified and tailored to specific applications by simple 
blending.  Further  improvements  of  polymer  blends  are  obtained  through  (a)  addition  of  a  third 
component, usually a block or graft copolymer, to impart compatibility between the two polymers;  
(b) chemical modification of one component aimed to create specific interactions with the other one. 
These strategies can solve problems arising from a bad interaction between the two polymers.  
Biodegradable  polymer  blends  usually  consist  in  mixing  natural  and  synthetic  biodegradable 
polymers. Most of polysaccharides are polydispersed in terms of the molecular mass, so they are more 
similar to synthetic polymers than to biopolymers such as proteins and nucleic acids. Blends based on 
polysaccharides  with  natural  and  synthetic  polymers  are  reported  26.  Blends  of  alginate  with 
polyvinyl alcohol, a synthetic polymer that has good susceptibility to biodegradation, are proposed due 
to their good compatibility 27,28. Addition of glycerol as a natural plasticizer to improve mechanical 
performances of alginate-based biofilms is also of interest 29. 
Blends  of  different  polysaccharides  present  the  advantage  that  the  components  are  highly 
compatible,  and  very  homogeneous  materials  are  obtained.  Interesting  results  were  obtained  for 
alginate/chitosan blends in which chitosan was previously modified by reaction of part of the amine 
functionalities with succinic anhydride in order to impart solubility at neutral pH, making it possible to 
prepare blends of the two polymers from water solution 30,31. Such blends show a synergistic effect 
of the chitosan in chelating calcium ions during the alginate gelation process, which in turn results in 
improved  mechanical  properties  of  the  corresponding  hydrogels.  Materials  based  on  such 
alginate/chitosan  blends  containing  calcium  sulfate  as  osteoinductive  phase  are  promising  for 
applications in bone regeneration 32.  
Blends with agar are of interest due to its ability to form reversible gels simply by cooling hot 
aqueous  solutions.  This  gel-forming  property  makes  blends  of  agar  with  biocompatible 
polysaccharides or synthetic polymers very appealing. Blends with agar usually improve the gelation Mar. Drugs 2010, 8 
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properties and water-holding capacity of the other polysaccharide component, and the obtained gels 
are not as strong and brittle as pure agar gels. These characteristics widen the field of potential interest 
of agar in biomedical applications. Blends of agar with alginate give films that are more flexible and 
easy to manage than pure agar, and moreover allow modulation of water permeability as a function of 
the blend composition, and have been proposed for dehydration of fresh fruits 33.  
2.4.2. Chemical Modifications 
Novel  materials  based  on  polysaccharides  are  being  intensively  sought,  both  through  bulk  and 
surface modifications. The chemical modification of chitin to produce chitosan represents the most 
fundamental process in this essay. This chemical modification is in fact particularly simple, since it 
just involves the hydrolysis of an amide moiety to generate the corresponding primary amino function. 
As in all polymer modifications, the ideal 100% conversion is very hard to achieve, and chitosans are 
therefore  a  whole  family  of  polymers,  characterized  by  their  average  molecular  weight  and  their 
degree of deacetylation, i.e., the percentage of amide groups converted into NH2 counterparts. 
The  ubiquitous  hydroxyl  groups  in  polysaccharides  are  the  most  obvious  source  of  chemical 
modification that  has  been  exploited, although all  other  functionalities present on polysaccharides 
(amino, acid, carboxylate) have been used for chemical reactions. A variety of chemical modifications 
(theoretically,  all  the  reactions  involving  these  functional  groups  may  be  performed  on 
polysaccharides)  have  been  realized.  Hydroxyls  are  used  for  oxidation  reactions  with  peroxide  to 
generate  the  more  reactive  aldheyde  groups,  for  esterification  with  acid  or  anhydrides  to  reduce 
hydrophylicity,  for  sulfonation  reactions  with  a  variety  of  sulfonating  agents,  for  bromination  or 
chlorination. Amino groups are more reactive than hydroxyls, so they must be protected to selectively 
address the reaction onto hydroxyls. Amines are specifically used for aqueous carbodiimide chemistry. 
Modified  polysaccharides  are  used  as  such  or  employed  for  successive  reactions,  including 
copolymerization. Several examples of the more explored chemical reactions that involve hydroxyls as 
well as other groups on polysaccharides, widely employed to modify properties such as solubility, to 
impart novel characteristics to the plain polymer, or to create sites for specific binding or interactions 
with other molecules of biological interest, are hereafter reported. 
2.4.2.1. Hydrophobic Modification  
Hydrophilic polymers modified by hydrophobic moieties represent a combination of surfactant and 
polymer properties in one molecule. As a consequence, they self-associate in aqueous solution to form 
complex micellar structures. This feature can be of interest for medical diagnosis application, as micelles 
are used as coating of colloidal metal particles for labeling biomolecules in immunological assays 34. 
Hydrophobically-modified polysaccharides are polysaccharides partially modified by cholesterol or 
other hydrophobic moieties. They are used as coating to stabilize liposomes for chemotherapy and 
immunotherapy 35. A selective uptake by cancer cells, particularly by human colon and lung cancer 
cells, has been shown by liposomes coated with cholesterol derivatives of polysaccharides bearing  
1-aminolactose  36.  Different  cholesterol-linked  celluloses  of  various  origins,  intended  for 
applications  as  bile  acid/cholesterol  sequestrants,  were  prepared  by  reaction  with  monocholesteryl 
succinate  37.  The  authors  found  that  the  introduction  of  a  mesogenic  substituent  may  induce  a Mar. Drugs 2010, 8 
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thermotropic behavior with formation of a mesophase. It has been also supposed that thermotropic 
cholesterol  derivatives  of  polysaccharides  would  have  even  enhanced  bile  acid/cholesterol 
sequestration, probably through mixed mesophase formation with the free bile acids/cholesterol. 
2.4.2.2. Depolymerization  
Depolymerization is often used to reduce molecular weight in view of specific applications, overall 
as patches for controlled release of drugs, because low molecular weight polymers have an increased 
amount of polar end groups. The patches are adhesives based on chemically and physically modified 
polysaccharides, which are partially depolymerized to provide a more effective topical and transdermal 
drug delivery system. Such patches were really found to be highly adhesive while providing superior 
drug penetration. 
Classical  depolymerization  methods  include  ozonolysis  in  aqueous  solutions  38,  oxidative 
depolymerization  induced  by  oxygen  radical  generating  systems  39,40,  specific  enzymatic 
degradation 41. A recent patent reports on a method for carrying out a targeted depolymerization of 
polysaccharides at increased temperatures, producing simultaneously polysaccharide derivatives with a 
desired degree of polymerization 42. The molecular weight of polysaccharides can be also reduced 
through chemical hydrolysis, ionizing radiation or electronic beam radiation 43–45. 
2.4.2.3. Sulfation 
Sulfated polysaccharides are polysaccharides containing high amounts of sulfate groups. They can be 
found in nature, but a lot of sulfated polysaccharides have been obtained by chemical modification. As 
sulfonating agents, sulfur trioxide-pyridin, piperidine-N-sulfonic acid, sodium sulfite and chlorosulfonic 
acid are the most used. The reaction may involve all the hydroxyls (primary and secondary) and the 
amines  eventually  present  on  polysaccharide,  or  it  can  be  targeted  to  a  specific  site.  Sulfated 
polysaccharides are known to have anti-retroviral 46 and/or antimalarial activity 47. This last can 
further be enhanced by a combination with artemisinin or its di-hydro derivative 48. Sulfated chitin and 
chitosan are found to be efficient carriers to deliver therapeutic agents across a mucosal membrane 49. 
A method for inhibiting or decreasing intestinal cholesterol and fatty acids absorption in man by 
oral administration of synthetic sulfated polysaccharides has been the matter of an American Patent 
50. The invention is based upon the discovery that sulfated polysaccharides are potent inhibitors of 
human pancreatic cholesterol esterase, the enzyme responsible for promoting the intestinal absorption of 
cholesterol and fatty acids. A variety of polysaccharide polymers can be sulfated to produce potent 
inhibitors of human pancreatic cholesterol esterase. Increasing inhibitory activities are realized from 
increased  molecular  weights  and  sulfation  at  a  specific  position;  increased  efficacy  is  obtained  by 
reducing  absorption  of  the  polysaccharides.  Accordingly,  the  methodology  includes  non-absorbable 
sulfated polysaccharides having a molecular weight greater than 10 kDa; furthermore, the presence of a 
3-sulfate on the sugar ring markedly enhances inhibition. Alginic acid, chitin and chitosan, agar, as well 
as other abundant and cheap natural polysaccharides as pectin (from vegetables and fruits), dextran and 
cellulose  (from  plants  and  trees),  have  been  reacted  in  a  controlled  manner  to  produce  sulfated 
derivatives. These derivatives are all water soluble, potent inhibitors of human pancreatic cholesterol 
esterase, whereas the parent starting polymers are either not inhibitory or poorly inhibitory. These Mar. Drugs 2010, 8 
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sulfated polysaccharides can be administrated orally in pharmaceutical forms such as tablets, capsules, 
liquids  and  powders.  Sulfation  of  polysaccharides  was  obtained  by  reaction  with  sulfur  
trioxide-pyridin. In the case of alginic acid, the reaction was performed directly on native polymer, or 
on the oxidized polymer, or on the product of oxidation followed by reductive amination of the native 
alginic acid, leading to different levels of sulfation (Figure 1). For chitin and chitosan, it is possible to 
target  the  reaction  on  two  sites  or  on  only  one  specific  site,  following  different  routes  of  
synthesis (Figure 2). 
Figure 1. The synthetic strategy for preparing alginic acid sulfated derivatives. 
 
Figure 2. The synthetic strategy for preparing chitin and chitosan sulfated derivatives [50].  
 Mar. Drugs 2010, 8 
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3. Examples of Applications of More Abundant Marine Polysaccharides in Pharmaceuticals 
3.1. Alginate 
Alginate is a natural occurring polysaccharide of guluronic (G) and mannuronic (M) acid, quite 
abundant in nature as structural component in marine brown algae (Phaeophyceae) and as capsular 
polysaccharides  in  soil  bacteria.  Brown  algal  biomass  generally  consists  of  mineral  or  inorganic 
components  and  organic  components,  these  last  mainly  composed  by  alginates,  fucans,  and  other 
carbohydrates. The isolating process of alginates from brown algal biomass is simple, including stages 
of pre-extraction with hydrochloric acid, followed by washing, filtration, and neutralization with alkali. 
Sodium alginate is  precipitated  from the solution  by alcohol  (isopropanol or ethanol) and usually  
re-precipitated (to achieve higher purity) in the same way. However, the real processing scheme for 
alginate production is quite complicated, including 15 steps [51]. 
Alginate instantaneously forms gel-spheres at pH > 6 by ionotropic gelation with divalent cations 
such as Ca
2+ [52], Ba
2+, or Zn
2+ and for this it is widely used for microencapsulation of drugs. On the 
other hand, at low pH, hydration of alginic acid leads to the formation of a high-viscosity “acid gel”. 
The ability of alginate to form two types of gel dependent on pH, i.e., an acid gel and an ionotropic 
gel,  gives  the  polymer  unique  properties  compared  to  neutral  macromolecules,  and  it  can  be  
tailor-made for a number of applications. 
The microencapsulation technique has been developed particularly for the oral delivery of proteins, 
as they are quickly denaturated and degraded in the hostile environment of the stomach. The protein is 
encapsulated  in  a  core  material  that,  in  turn,  is  coated  with  a  biocompatible,  semi  permeable 
membrane, which controls the release rate of the protein while protecting it from biodegradation. Due 
to its mild gelation conditions at neutral pH, alginate gel can act as core material in this application, 
while poly(ethylene glycol) (PEG), which exhibits properties such as protein resistance, low toxicity 
and immunogenicity [53], together with the ability of preserving the biological properties of proteins 
[54,55], can act as a coating membrane. A chitosan/PEG-alginate microencapsulation process [56], 
applied to biological macromolecules such as albumin or hirudin [57], was reported to be a good 
candidate for oral delivery of bioactive peptides.  
Several  examples  of  alginate-encapsulated  drugs,  other  than  proteins,  can  also  be  found  in 
literature.  Qurrat-ul-Ain  et  al.  [58]  reported  that  alginate  microparticles  showed  better  drug 
bioavailability and reduction of systemic side effects compared with free drugs in the treatment of 
tuberculosis. Polyelectrolyte coating of alginate microspheres showed to be a promising tool to achieve 
release systems characterized by approximately zero-order release kinetics, release up to 100% of 
entrapped drug (dexamethasone) within 1 month, and improved biocompatibility [59].  
Composites technology has been applied to alginate for drug delivery purposes. As an example, 
montmorillonite-alginate  nanocomposites  have  been  recently  proposed  as  a  system  for  sustained 
release of B1 and B6 vitamines [60]. The vitamins intercalated in the nanocrystals of the inorganic 
phase, and successively the hybrid B1/B6 montmorillonite (MMT) is further used for the synthesis of 
B1/B6-MMT-alginate nanocomposite.  
In their simplest design, oral controlled-release dosage forms made from alginates are monolithic 
tablets in which the drug is homogeneously dispersed. Drug release is controlled by the formation of a 
hydrated viscous layer around the tablet, which acts as a diffusional barrier to drug diffusion and water Mar. Drugs 2010, 8 
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penetration. Water soluble drugs are mainly released by diffusion of dissolved drug molecules across 
the gel layer, while poorly soluble drugs are mainly released by erosion mechanisms. Modulation of 
drug release rate has been achieved by incorporating pH-independent hydrocolloids gelling agents or 
adding polycationic hydrocolloids such as chitosan [61,62]. A number of mucoadhesive systems based 
on alginate have been developed [63,64]. The main shortcoming of alginates consists in their rapid 
erosion at neutral pH; furthermore, the adhesion to mucosal tissues is reduced when cross-linked with 
divalent  cations.  Alginates  have  been  extensively  used  to  modify  the  performances  of  other 
polysaccharides, such as chitosan, through the realization of alginate coated chitosan microspheres 
[65]. In the literature, it is also possible to find acrylic modified polysaccharides developed with the 
aim to obtain a finer control over release rate or to improve adhesive properties [66,67].  
The modification of sodium alginate with amine and/or acid moieties with the aim to optimize their 
properties for drug delivery applications by modulating the time of erosion, the rate of release of drugs, 
and  the  adhesion  to  substrates  has  been  attempted  by  Laurienzo  et  al.  [68].  In  this  article,  graft 
copolymers based on alginate and acrylic polymers were synthesized by radical polymerization of the 
acrylic  monomers  or  oligomers  in  the  presence  of  sodium  alginate.  The  authors  found  that  the 
modification  of  alginate  network  significantly  affects  water  uptake  and  erosion  rate  of  matrices 
prepared  by  direct  compression.  As  a  consequence,  the  release  rate  and  mechanism  of  a  highly  
soluble-low molecular weight drug was found to be controlled mainly by either a diffusion/erosion or 
erosion mechanism, depending on polymer type and medium pH. Furthermore, they found increased 
adhesive  properties  of  the  copolymers,  and  concluded  that  they  might  be  good  candidates  in 
formulations for mucoadhesive systems for the treatment of heartburn and acid reflux, because of the 
possibility to improve the gastric protective coating action. 
Hydrophobically-modified alginates can be prepared by oxidation followed by reductive amination 
of the 2,3-dialdehydic alginate [69]. The ability of alginate to bind cations renders these modified 
alginates interesting as biosurfactants environmentally friendly for the removal of organics and metal 
divalent cations.  
Among the possible applications of alginate gel systems, one of the most promising is for tissue 
regeneration.  The  main  drawback  of  alginate  matrix  gels  is  represented  by  their  high  density  of 
network,  which  limits  the  cell  growth  [70];  moreover,  cell  anchorage,  a  strict  requirement  for 
proliferation and tissue formation, is limited on alginate gels, because of its hydrophilic nature. PEG 
copolymers  are  used  to  improve  the  biocompatibility  of  polysaccharides.  Several  PEG-alginate 
systems for cell entrapment have been reported [71]; recently, a new alginate-g-PEG copolymer has 
been  described  [72].  The  synthesis  goes  via  hydrophobization  of  alginate  with  alkylic  amines; 
successively, the secondary amines grafted onto the alginate react with a low molecular weight PEG 
functionalized with a carboxylic acid group at one end, to produce an alginate-g-PEG copolymer. As 
the reactions do not involve the carboxylic acid groups of the alginate, the ability to cross-link via 
ionic interactions is retained. The obtained copolymers show the double function to form micelles in 
water above a critical concentration and to form gels with divalent cations.  
Alginate for Wound Healing 
Alginate dressings for wound healing have been successfully applied for many years to cleanse a 
wide variety of secreting lesions, and they still remain widely used in many circumstances. Alginate Mar. Drugs 2010, 8 
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gels  dressings  are  highly  absorbent,  and  this  limits  wound  secretions  and  minimizes  bacterial 
contamination. Alginate fibers trapped in a wound are readily biodegraded [73]. Alginate dressings 
maintain  a  physiologically  moist  microenvironment  that  promotes  healing  and  the  formation  of 
granulation tissue. Alginates can be rinsed away with saline irrigation, so removal of the dressing does 
not interfere with healing granulation tissue. This makes dressing changes virtually painless. Alginate 
dressings are very useful for moderate to heavily exudating wounds [74].  
The healing of cutaneous ulcers requires the development of a vascularized granular tissue bed, the 
filling of large tissue defects by dermal regeneration, and the restoration of a continuous epidermal 
keratocyte  layer.  These  processes  were  modeled  in  vitro  in  one  study  utilizing  human  dermal 
fibroblasts, microvascular endothelial cells (HMEC), and keratocyte cultures [75]. In this study, the 
calcium alginate was found to increase the proliferation of fibroblasts but decreased the proliferation of 
HMEC and keratocytes. In contrast, the calcium alginate decreased fibroblast motility but had no 
effect on keratinocyte motility. There was no significant effect of calcium alginate on the formation of 
capillary-like structures by HMEC. The effects of calcium alginate on cell proliferation and migration 
may have been mediated by released calcium ions. These results suggest that the calcium alginate 
tested may improve some cellular aspects, but not others. 
Alginates have been shown to be useful also as hemostatic agents for cavity wounds [76]. A study 
compared the effects of calcium and zinc containing alginates and non-alginate dressings on blood 
coagulation and platelet activation [77]. The study showed that alginate materials activated coagulation 
more than non-alginate materials. The extent of coagulation activation was affected differently by the 
alginate M or G group concentration. Moreover, it was demonstrated that alginates containing zinc 
ions  had  the  greatest  potentiating  effect  on  prothrombotic  coagulation  and  platelet  activation. 
However, there has been one report of a florid foreign body reaction after the use of an alginate 
dressing to obtain hemostasis in an apicectomy cavity. The case suggests that alginate fibers left in situ 
may elicit a long-lasting and symptomatic adverse foreign body reaction [78]. 
3.2. Chitosan 
Chitosan  is  a  copolymer  of  -(14)-linked  2-acetamido-2-deoxy-D-glucopyranose  and  
2-amino-2-deoxy-D-glucopyranose. It is obtained by deacethylation of the natural occurring chitin. 
Chitin is extracted from the exoskeleton of marine organisms, mainly crabs and shrimps, as described 
by Burrows [79]. Briefly, the exoskeletons are crushed and washed, then treated with boiling sodium 
hydroxide to dissolve the proteins and sugars, thus isolating the crude chitin. The major applications of 
chitosan  are  in  biomaterials,  pharmaceuticals,  cosmetics,  metal  ion  sequestration,  agriculture,  and 
foodstuff  treatment  (flocculation,  clarification,  etc.,  because  of  its  efficient  interaction  with  other 
polyelectrolytes). Development of chitosan chemistry is relevant in biomedical science, particularly in 
the topic of drug delivery [80,81]. Unlike its precursor chitin, which is insoluble in most common 
solvents,  chitosan  can  readily  be  spun  into  fibers,  cast  into  films,  or  precipitated  in  a  variety  of 
micromorphologies from its acidic aqueous solutions. Electrospinning from acetic acid solutions to 
provide nanofibers has also been reported [82]. The excellent ability to form porous structures simply 
by freezing and lyophilizing its solutions, or by simple techniques such as “internal bubble process” 
[83],  makes  chitosan  a  versatile  biopolymer  for  tissue  engineering,  particularly  in  orthopedics  for 
cartilage  [84]  and  bone  regeneration  [85].  Possible  chitosan  matrix  preparations  for  cell  cultures Mar. Drugs 2010, 8 
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include gels [86], sponges [87], fibers [88], or porous compositions of chitosan with ceramic [89] or 
other polymeric materials such as collagen or gelatin [90,91]. Chitosan has been combined with a 
variety of materials such as alginate, hydroxyapatite, hyaluronic acid, calcium phosphate, PMMA, 
poly-L-lactic acid (PLLA), and growth factors for potential application in cell-based tissue engineering 
[92]. Alginate is a candidate biomaterial for cartilage engineering but exhibits weak cell adherence. 
Iwasaki et al. [93] reported on alginate-based chitosan hybrid polymer fibers which showed increased 
cell attachment and proliferation in vitro compared to alginate fibers. In addition, when it is combined 
with alginates the system acts as a biomimetic membrane which controls the release of bioactive 
macromolecules  such  as  hirudin  [94].  Interpenetrated  polymer  networks  (IPNs)  of  chitosan  and 
poly(acrylic  acid)  (PAA)  for  applications  as  biodegradable  filling  systems  and  controlled  release 
devices have been prepared by radical polymerization of acrylic acid in the presence of chitosan [95]. 
In orthopedics, chitosan is used as an adjuvant with bone cements to increase their injectability 
while keeping the chemical-physical properties (time setting and mechanical characteristics) suitable 
for surgical use [96]. 
Chitosan can be modified in order to improve compatibility in blends with other polymers and to 
impart  solubility  in  water  or  in  common  organic  solvents  such  as  chloroform,  pyridine, 
tetrahydrofuran.  Organically  soluble  derivates  of  chitosan  can  be  used  to  formulate  by-designed 
materials  for  biomedical  applications  such  as  polymeric  drugs  and  artificial  organs.  Acylation, 
alkylation and phthaloylation reactions have been widely used [97–101]. Novel formulations based on 
a combination of chitosan with polyol-phosphate salts have allowed neutral solutions to be obtained 
without any chemical modification of the chitosan [102]. These formulations possess a physiological 
pH and can be held liquid below room temperature for encapsulating living cells and therapeutic 
proteins; they form monolithic gels at body temperature. Therefore, when injected in vivo the liquid 
formulations turn into gel implants in situ. This system was used successfully to deliver biologically 
active growth factors in vivo as well as an encapsulating matrix for living chondrocytes for tissue 
engineering applications. 
Due  to  its  favorable  gelling  properties,  chitosan  can  deliver  morphogenic  factors  and 
pharmaceutical agents in a controlled fashion. Methodologies to produce micro and nanoparticles of 
chitosan  and  its  derivates  for  drug  delivery  include  spray-drying  and  water-in-oil  emulsions 
techniques. Drug release from chitosan microparticles can be controlled by cross-linking the matrix. 
Microparticles can be cross-linked by chemicals such as glutaraldheyde, genipin, diisocyanates and 
ethylene  glycol  diglycidyl  ether,  or  by  ionic  agents,  or  by  a  combination  of  them  [103].  Among 
chemical  agents,  genipin,  a  naturally  occurring  cross-linker,  significantly  less  cytotoxic  than 
glutaraldehyde [104], has been largely employed for crosslinking of hydrogels and beads. Among 
ionic agents, tri-polyphosphate (TPP), a non toxic and multivalent polyanion, was reported to form gel 
by  ionic  interaction  between  positively  charged  amino  groups  of  chitosan  and  negatively  charged 
counterion  of  TPP  [105–108].  By  controlling  the  pH  and  the  concentration  of  TPP  solutions,  
cross-linked chitosan microspheres for a potentially controlled release of drugs have been obtained 
[109]. In alginate-chitosan mixed systems, cross-linked microcapsules are prepared either by dropping 
a solution of sodium alginate into an acidic solution containing chitosan, or by incubating calcium 
alginate beads in a chitosan solution, or by dropping a chitosan solution into a TPP solution containing 
sodium alginate [110]. Mar. Drugs 2010, 8 
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Many applications have been proposed for chitosan-based delivery devices. Strong electrostatic 
interactions with mucus open the doors to possible applications as gastrointestinal or nasal delivery 
systems  [111,112].  Additionally,  the  cationic  character  of  chitosan  imparts  particular  possibilities.  
pH-sensitive microspheres made of hybrid gelatine/chitosan polymer networks have been developed 
and showed to release drugs only in acidic medium [113]. A pH-sensitive, chitosan-based hydrogel 
system  for  controlled  release  of  protein  drugs  cross-linked  by  genipin  was  developed  also  by  
Chen et al. [114]. 
Brush-like copolymers of chitosan with poly(-caprolactone) (PCL), polyethylene glycol (PEG) or 
their copolymers have been prepared following different procedures of synthesis. [115–119]. Such 
amphiphilic copolymers are able to self-assembly in aqueous solutions. Nanomicelles obtained from 
chitosan-g-PCL copolymers have been successfully tested as carriers of hydrophobic drugs [120]. 
Chitosan  and  its  derivates  or  salts  have  been  extensively  investigated  for  alternative  routes  of 
administration  of  insulin,  such  as  oral,  nasal,  transdermal  and  buccal  delivery  systems  [121,122]. 
Chitosan is mucoadhesive and able to protect the insulin from enzymatic degradation, prolong the 
retention time of insulin, as well as open the inter-epithelial tight junction to facilitate systemic insulin 
transport.  Targeted  delivery  of  insulin  is  deemed  possible  in  future  through  using  chitosan  with 
specific adhesiveness to the intended absorption mucosa. Water-soluble low molecular weight chitosan 
renders insulin able to be processed under mild conditions, and sulfated chitosan markedly opens the 
paracellular channels for insulin transport. The development of insulin carriers using chitosan base 
and/or  its  derivates  involves  many  techniques  such  as  nanocomplexation,  mixing,  solubilization, 
ionotropic gelation, coacervation, layer-by-layer encapsulation, water-in-oil emulsification, membrane 
emulsification, lyophilization, compression, capsulation, casting, adsorption and/or absorption processes.  
The cationic nature of chitosan allows it to complex DNA molecules, making it an ideal candidate 
for gene delivery strategies. Chitosan nanoparticles appear to control the release of DNA and prolong 
its action both in vitro and in vivo [123–125]. Chitosan in fact provides protection against DNAase 
degradation  [126].  Chitosan  was  selected  also  as  a  coating  material,  alone  or  in  blends  with 
polyvinylalcohol, for cationic surface modification of biodegradable nanoparticles for gene delivery 
[127]. These cationic surface modified nanospheres can readily bind DNA by electrostatic interaction, 
simply mixing their aqueous solutions. 
Chitosan  nanoparticles  have  been  used  also  to  transport  small  interfering  RNAs  (siRNA).  The 
cellular RNA interference machinery is now used in cancer gene therapy to turn off, for instance, 
oncogene  expression.  Katas  and  Alpar  [128]  first  studied  the  interaction  behavior  of  siRNA  and 
chitosans given that the structure and size of siRNA are quite different to that of pDNA. Studies 
in vitro demonstrated that chitosan nanoparticles are able to mediate gene silencing. Furthermore, the 
transfection efficiency of RNA depends on its association with chitosan. Indeed, entrapping siRNA 
using ionic gelation showed a better biological effect than simple complexation or siRNA adsorption 
onto the chitosan nanoparticles. This might be attributed to stronger interactions between the chitosan 
and siRNA and a better loading efficiency when using ionic gelation. 
Another interesting property of chitosan is its intrinsic antibacterial activity [129]. For this reason, 
chitosan is a preferred carrier for drug delivery of antibiotics, combining its intrinsic antibacterial 
activity with that of the bound antibiotic. Studies have shown that chitosan may reduce the rate of 
infections induced by bacteria such as Staphylococcus in rabbits [130]. The mechanism involves its Mar. Drugs 2010, 8 
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cationic  amino  groups,  which  associate  with  anions  on  the  bacterial  cell  wall,  suppressing 
biosynthesis; moreover, chitosan disrupts the mass transport across the cell wall accelerating the death 
of bacteria. The antibacterial activity is retained also when it is combined with other polymers [131]. 
Blends of chitosan with polyvinyl alcohol (PVA) crosslinked by gamma radiation have been prepared 
for wound dressing [132]. Chitosan was used to prevent microbiological growth, such as fungi and 
bacteria, on the PVA polymer. Moreover, chitosan has antiacid and antiulcer characteristics, which 
prevents or weakens drug irritation in the stomach [133].  
Nanostructured surface coatings based on polysaccharides have been obtained by a combination of 
chitosan with hyaluronic acid and heparin [134]. The engineering of the nanoscale surface features of 
biologically active materials is an important goal for biomaterials scientists, as it strongly influences a 
variety of responses of mammalian cells towards biomaterials. 
3.3. Agar/Agarose and Carrageenans 
Agar (or agar-agar) is a phycocolloid, which is constructed from complex saccharide molecules 
(mainly,  -D-galactopyranose  and  3,6-anhydro--L-galactopyranose  units)  extracted  from  certain 
species of red algae (Gelidium, Gelidiela, Pterocladia, Gracilaria, Graciliaropsis, and Ahfeltia) [135]. 
Genetic  manipulation  of  agarophytes  in  the  development  stages  promises  to  minimize  seasonal 
variations in plant growth and agar quality. Agar and its variant agarose contain also variable amounts 
of sulfate, piruvate and uronate substituents. 
Agar is insoluble in cold water but is soluble in boiling water. Agar dissolved in hot water and 
permitted to cool will form thermally reversible gels (the gel will melt when heated and reformed 
again when cooled), without the need of acidic conditions or oxidizing agents. This characteristic gives 
agars the ability to perform a reversible gelling process without losing their mechanical and thermal 
properties. The significant thermal hysteresis of the gel is another important property for commercial 
applications. The gelling process in agar is due to the formation of hydrogen bonds in a continuous 
way [136–139]. Gelation occurs as a result of a coil-double helix transition [140–142]; helices interact 
among themselves and the gel is formed by linked bundles of associated right-handed double helices. 
The resulting three-dimensional network is capable of immobilizing water molecules in its interstices 
[143]. Characteristically, solutions containing 1–2% agar by weight will gel at about 35 ° C and will 
melt  at  about  85  °C .  The  1–2%  (w/w)  agar  gels  are  strong  and  brittle.  Typically,  a  force  of  
500–1000  g cm
−2  is  required  to  break  these  gels.  The  strength  and  brittleness  of  agar  gels  are 
proportional to the amount of 3-6-anhydro--L-galactopyranose in the agar. An alternatively way to 
cross-link  agar  is  via  chemical  agents  [144].  By  crosslinking  with  glutaraldehyde,  agar  forms 
superabsorbent hydrogels. 
The ionic nature of the agar molecules permits to complex with proteins. The presence of proteins 
in wine, juice and vinegar clouds these products. Agar is added during processing to bind with proteins 
impurities. This facilitates the removal of proteins by filtration or centrifugation. 
Agar has medicinal or pharmaceutical industrial applications including use as suspending agent for 
radiological  solutions  (barium  sulfate),  as  a  bulk  laxative  as  it  gives  a  smooth  and  non-irritating 
hydrated bulk in the digestive tract, and as a formative ingredient for tablets and capsules to carry and 
release  drugs.  Pharmaceutical  grade  agar  has  a  viscous  consistency.  In  microbiology,  agar  is  the 
medium  of  choice  for  culturing  bacteria  on  solid  substrate.  Agar  is  also  used  in  some  molecular Mar. Drugs 2010, 8 
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microbiology  techniques  to  obtain  DNA  information  [145].  More  recently,  agar  was  used  in  a  
newly-developed  medium,  i.e.,  combined  deactivators-supplemented  agar  medium  (CDSAM),  to 
evaluate the viability of dermatophytes in skin scales [146]. The experimental data from this clinical 
study indicate that CDSAM was more useful than standard media in accurately evaluating the efficacy 
of antifungal drugs. Agar proportion method for drug susceptibility tests has been used since 1957 
[147]. Recently, the test has been replaced by more rapid tests [148]. 
The possibility to use agar and agarose beads for sustained release of water soluble drugs has been 
investigated  [149].  Agarose  has  a  significantly  lower  sulfate  content,  better  optical  clarity  and 
increased gel strength with respect to agar, but it is considerably more expensive [150]. Agar beads 
containing phenobarbitone sodium as a water soluble and hypnotic drug were prepared [151]. The 
encapsulation procedure consists in dissolving the drug in a hot (around 70 °C ) agar aqueous solution 
and then dropping the solution in a cold bath containing a non-solvent for agar (acetone or ethyl 
acetate). Agar beads instantaneously form by gelification. The results of dissolution and release studies 
indicated  that  agar  beads  could  be  useful  for  the  preparation  of  sustained  release  dosage  forms, 
although no many further studies have been developed. 
Carrageenan, as well as agar and agarose, is a sulfated polysaccharide obtained by extraction with 
water or alkaline water of certain Rhodophyceae (red seaweed). It is a hydrocolloid consisting mainly 
of  the  potassium,  sodium,  magnesium,  and  calcium  sulfate  esters  of  galactose  and  
3,6-anhydro-galactose copolymers. 
Plain carrageenans, as well as agar, are mainly used as food additive, but increasing attention is 
given to possible biomedical applications, in combination with synthetic polymers. The synthesis of 
agar-graft-polyvinylpyrrolidone  (PVP)  and  k-carrageenan-graft-PVP  blends  by  a  microwave 
irradiation method has been reported [152]. The physicochemical and rheological properties of the 
corresponding hydrogels were studied and compared with control agar and k-carrageenan hydrogels. 
The  novel  blend  hydrogels  were  found  to  be  not  as  strong  and  showed  better  spreadability  and  
water-holding capability, so they are potentially useful in moisturizer formulations and active carriers 
of drugs. The use of blended PVP with agar in hydrogel dressings has also been reported [153]. 
3.4. Exopolysaccharides (EPS) 
Microbial polysaccharides represent a class of important products that are of growing interest for 
many sectors of industry. The advantages of microbial polysaccharides over plants polysaccharides are 
their novel functions and constant chemical and physical properties. A number of common marine 
bacteria widely distributed in the oceans can produce EPSs; nevertheless, most of these EPSs remain 
poorly understood, and only a few of them have been fully characterized. The roles of microbial EPSs 
in the ocean are briefly described in Table 2. Mar. Drugs 2010, 8 
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Table 2. Some roles of microbial exopolymeric material (EPSs) in the marine environment. 
Adapted from [151]. 
Role of Exopolymer  Example 
Assists in attachment to surfaces 
Exopolymers  of  marine  Vibrio  MH3  were  involved  in 
reversible attachment. 
Cross-linking of adjacent polysaccharide chains aided in 
permanent adhesion. 
Facilitates biochemical interactions 
between cells 
Exopolymer  mediated  bacterial  attachment  to  the  polar 
end of blue-green N2-fixing alga. EPS aided attachment 
to  symbiotic  host  such  as  vent  tube  worm  to  absorb 
metals and detoxify microenvironment. 
Exopolymer buffered against sudden osmotic changes. 
Provides protective barrier around the cell 
Bacteria in aggregates were less preferred by grazers than 
freely suspended bacteria. 
EPS-producing  deep-sea  hydrothermal  vent  bacteria 
showed  resistance  to  heavy  metals.  Metal  binding 
involves cell wall components as well as polysaccharides. 
Exopolymer  in  sea-ice  brine  channels  provided 
cryoprotection  by  interacting  with  water  at  low 
temperature to depress freezing point. 
Nutrient uptake by bacteria in aggregates was higher than 
for free-living cells in low nutrient systems. 
Absorbs dissolved organic material 
Porous  and  hydrated  matrix  acts  like  a  sponge  and 
sequesters and concentrates dissolved organics. 
In  recent  years,  there  has  been  a  growing  interest  in  isolatin g  new  exopolysaccharides  
(EPSs)-producing  bacteria  from  marine  environments,  particularly  from  various  extreme  marine 
environments [154]. Many new marine microbial EPSs with novel chemical compositions, properties 
and structures have been found to have potential applications in fields such as adhesives, textiles, 
pharmaceuticals  and  medicine  for  anti-cancer,  food  additives,  oil  recovery  and  metal  removal  in 
mining and industrial waste treatments, etc. General information about the EPSs produced by marine 
bacteria, including their chemical compositions, properties and structures, together with their potential 
applications in industry, are widely reported [155]. Components more commonly found in marine 
EPSs  are  listed  in  Table  3.  Some  more  recent  and  specific  examples  from  literature  are 
hereafter illustrated. Mar. Drugs 2010, 8 
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Table 3. Sugar and non sugar components of bacterial exopolysaccharides [151]. 
Type  Component  Example  Mode of Linkage 
Sugar  Pentoses  D-Arabinose 
D-Ribose 
D-Xylose 
 
  Hexoses  D-Glucose   
    D-Mannose   
    D-Galactose   
    D-Allose   
    L-Ramnose   
    L-Fucose   
  Amino sugars  D-Glucosamine   
    D-Galactosamine   
  Uronic acids  D-Glucuronic acid   
    D-Galacturonic acid   
Non sugar  Acetic acid    O-acyl, N-acyl 
  Succinic acid    O-acyl 
  Pyruvic acid     Acetal 
  Phosphoric acid    Ester, Diester 
  Sulfuric acid    Ester 
3.4.1. Biological Activity of EPSs 
EPS2,  a  polysaccharide  produced  by  a  marine  filamentous  fungus  Keissleriella  sp.  YS  4108 
exhibited profound free radical-scavenging activities [156,157]. Antioxidants are commonly used in 
processed foods, as they could alleviate the oxidative damage of a tissue indirectly by increasing cells’ 
natural defenses and directly by scavenging the free radical species [158,159]. As most of antioxidants 
used are synthetic and have been suspected of being responsible for liver damage and carcinogenesis 
[160,161], it is essential to develop and utilize effective natural antioxidants. Sun, Mao et al. [162] 
isolated three different exopolysaccharides from marine fungus Penicillium sp. F23-2, and evaluated 
their  antioxidant  activity  by  assays  in  in  vitro  systems.  The  results  showed  that  the  three 
polysaccharides possessed good antioxidant properties, especially scavenging abilities on superoxide 
radicals and hydroxyl radicals. 
Interesting studies concern with the roles of carbohydrates as recognition sites on the cell surfaces 
[163]. It has been demonstrated that micro-organisms must specifically attach to the host cell to avoid 
being washed away by secretions. Such attachment would permit colonization or infection, sometimes 
followed by membrane penetration and invasion. Bergey and Stinson [164] and Bellamy et al. [165] 
provide some evidence of the participation of the carbohydrates in the cellular recognition process of 
the interaction between host and pathogen. It is an attractive possibility to use carbohydrate-based 
drugs for blocking the early stages of an infection process. In particular, sulfated polysaccharides are 
involved  in  biological  activities  such  as  cell  recognition,  cell  adhesion,  or  regulation  of  receptor 
functions  [166–168].  Obtaining  sulfated  polysaccharides  from  algae  has  made  development  of 
biotechnology for obtaining new therapeutic products easier. The use of bioactive compounds from 
microalgae has been considered recently as an alternative to prevent microbial infections in animals Mar. Drugs 2010, 8 
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and humans and to decrease the use of antibiotics [169]. Ascencio et al. [170] identified heparan 
sulfate  glycosaminoglycan  as  putative  host  target  for  Helicobacter  pylori  adhesion.  A  number  of 
marine  and  freshwater  microalgal  strains  for  the  production  of  sulfate  exopolysaccharides  was 
screened by these authors to evaluate whether these exopolysaccharides can block adherence to human 
and fish cells of human gastrointestinal pathogens, such as H. pylori and Aeromonas veronii. Results 
indicate the sulfated polysaccharides of some species of microalgae inhibit the cytoadhesion process of 
H. pylori to animal cells. The treatment with sulfated polysaccharides could so be used to block the 
initial process of colonization of the host by H. pylori, so it may represents an alternative prophylactic 
therapy in microbial infections where the process of cytoadhesion of host to pathogen is likely to be 
blocked. Such a therapy could replace the use of antibiotics and antiparasitic drugs that are always 
aggressive towards the host and, moreover, can generate resistant strains to the antibiotic, making it 
necessary to use second generation antibiotics [171,172]. 
Many  polysaccharides  have  an  anticancer  activity.  In  general,  the  action  mechanism  is  via 
macrophage  activation  in  the  host  [173,174].  More  recently,  Matsuda  et  al.  [175]  reported  that  a 
sulfated exopolysaccharide produced by Pseudomonas sp. shows a cytotoxic effect towards human 
cancer cell lines such as MT-4. These findings have resulted in further interest in this polysaccharide 
as a new anticancer drug suitable for clinical trials. 
Several marine bacteria isolated from deep-sea hydrothermal vents have demonstrated their ability 
to produce, in aerobic conditions, unusual EPS. These EPS could provide biochemical entities with 
suitable  functions  for  obtaining  new  drugs.  They  present  original  structural  feature  that  can  be 
modified to design compounds and improve their specificity. 
Studies  aimed  to  discover  biological  activity  of  such  new  EPS  were  performed  by  
Colliec-Jouault  et  al.  [176].  An  EPS  secreted  by  Vibrio  diabolicus,  a  new  species  isolated  from 
Alvinella pompejana of Pompei, was evaluated on the restoration of bone integrity in an experimental 
model  and  was  demonstrated  to  be  a  strong  bone-healing  material.  High  molecular  weight  EPS 
produced from fermentation of Vibrio diabolicus stocks has been implanted in bone injuries created in 
the cranium of a mouse, and compared with analogous injuries not treated or treated with collagene as 
a reference. After 15 days, a 95% healing was found for the injuries treated with the EPS, while less 
than 30% healing was found for untreated or collagene treated injuries. 
Another  EPS  produced  by  Alteromonas  infernos,  a  new  Alteromonas  species  isolated  in  a 
hydrothermal vent from the Guaymas region, was really modified in order to obtain new heparin-like 
compounds [177]. The native EPS was depolymerized by radical mechanism or chemical hydrolysis, 
and  low-mass  derivatives  (around  24,000  Da)  were  sulfated  to  obtain  an  “heparin-like”  or  
“heparin-mimetic”  compound.  Unlike  the  native  EPS,  the  resulting  sulfated  EPS  presented 
anticoagulant properties as heparin. 
3.4.2. Exopolysaccharides from Cyanobacteria 
Cyanobacteria, also known as blue-green algae or blue-green bacteria because of their color (the 
name comes from Greek: kyanó s = blue), are a significant component of the marine nitrogen cycle and 
an important primary producer in many areas of the ocean. They are also found in habitats other than 
the  marine  environment;  in  particular,  cyanobacteria  are  known  to  occur  in  both  freshwater, 
hypersaline inland lakes and in arid areas where they are a major component of biological soil crusts. Mar. Drugs 2010, 8 
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Since the early 1950s, more than one hundred cyanobacteria strains of different genera have been 
investigated regard to the production of exocellular polysaccharides. Such polysaccharides are present 
as outermost investments forming sheaths, capsules and slimes that protect the bacterial cells from the 
environment. Moreover, most polysaccharide-producing cyanobacteria release aliquots of capsules and 
slimes as soluble polymers in the culture medium (RPS)[178]. In recent years the interest towards such 
cyanobacteria has greatly increased, in particular towards those strains that possess abundant capsules 
and slimes and so release large amount of soluble polysaccharides, which can be easily recovered from 
liquid culture. 
The chemical and rheological analyses show that RPS are complex anionic hetero-polymers, in 
about 80% cases containing six to ten different monosaccharides, glucose being the most abundant 
[179].  This  characteristic  is  unusual  in  EPS  of  industrial  interest,  which  usually  contain  a  lower 
number of monosaccharides, and is of great significance [180]. Actually, a large number of different 
monosaccharides in only one polymer makes many structures and architectures possible [181], thus 
increasing the chance of having a polymer with peculiar properties, not common to currently utilized 
products.  The  rheological  properties  of  RPSs’  aqueous  solutions  make  them  useful  as  thickening 
agents for water solutions, together with their ability to stabilize the flow properties of their own 
solutions under drastic changes of pH, temperature and ionic strength [182,183]. 
Another important feature of such RPS is their anionic nature. In fact, in about 90% cases, one or 
more uronic acids are present; moreover, RPS also contain sulfate groups. Both uronic and sulfate 
groups contribute to impart a high anionic density to the polymer. The anionic charge is an important 
characteristic for the affinity of these EPS towards cations, notably metal ions. Almost all RPS have 
significant levels of non-saccharidic components, such as ester-linked acetyl and/or pyruvyl groups 
and peptidic moieties which, along with other hydrophobic components as the deoxysugars fucose and 
rhamnose,  contribute  to  a  significant  hydrophobic  behavior  of  these  otherwise  hydrophilic 
macromolecules, conferring them emulsifying properties [184,185].  
The presence of charged groups on the macromolecules may lead to several interesting industrial 
applications:  their  capability  to  bind  water  molecules  can  be  exploited  by  the  cosmetic  and 
pharmaceutical industries for product formulations [186]. A promising new field of application that 
attracted much attention is related to antiviral activity of some RPSs isolated from the blue-green alga 
Spirulina platensis [187,188]. The presence in these polysaccharides of significantly high amounts of 
sulfate  groups,  indeed,  is  accounted  for  their  antiviral  activity,  and  an  increasing  amount  of  data 
is available. 
4. Conclusions 
A brief review of recent advances in applications of polysaccharides of marine origin in the medical 
and pharmaceutical fields has been reported. Many experimental results clearly indicate that novel 
exciting and promising marine sources of polysaccharides of applied interest, such as cyanobacteria 
and  thermophylic  or  hyperthermophylic  bacteria  from  extreme  habitats,  are  emerging.  Further 
investigations with a multidisciplinary approach are imperative in order to develop novel polymers 
useful as drugs or for healthcare in a larger sense. Mar. Drugs 2010, 8 
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